Sciele Pharma, Inc. and Plethora Solutions Holdings Announce Completion of Patient Recruitment for Global Phase III Trial of PSD502 for Premature Ejaculation
Published: Feb 18, 2009
ATLANTA & LONDON--(BUSINESS WIRE)--Sciele Pharma, Inc., a Shionogi company, and Plethora Solutions Holdings PLC (“Plethora,” AIM: PLE), today announced the completion of patient recruitment of the PSD502 registration program for the treatment of premature ejaculation (PE). The preliminary results from this North American study are expected in mid-year 2009. A parallel European Phase III study of PSD502 concluded successfully in November 2008 with a positive outcome that was both clinically and statistically significant.